MedTrace Logo

MAGESTIC Trial: MiRNA in Detecting Active Germ Cell Tumors in Early Suspected and MetastaTIC Disease Trial

NCT06060873 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 418

Last updated 2026-04-13

No results posted yet for this study

Summary

This study evaluates the accuracy of blood-based biomarker testing to predict the presence of active testicular cancer.

Conditions

  • Malignant Testicular Germ Cell Tumor

Interventions

OTHER

Clinical Stage I Disease

Patients undergo blood sample collection during screening and throughout the study. Based on results, patients will undergo a primary RPLND surgery or standard surveillance. Surveillance will follow until year 5.

OTHER

Clinical Stage I with relapse, CSII Disease

Patients undergo blood sample collection during screening and throughout the study. Based on results, patients will undergo a primary RPLND surgery or reassessment and then surveillance will follow until year 5.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Southern California

    lead OTHER

Principal Investigators

  • Siamak Daneshmand, MD · University of Southern California

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-08
Primary Completion
2028-06-08
Completion
2028-12-08

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06060873 on ClinicalTrials.gov